Recent

% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, AŞ Message Board

debdoesbios 616 posts  |  Last Activity: Oct 19, 2015 1:25 PM Member since: Dec 19, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Billy

    by freetoquestionu Oct 19, 2015 12:52 PM
    debdoesbios debdoesbios Oct 19, 2015 1:25 PM Flag

    Did you mean sells for $40 a share?

  • Reply to

    Have 40,000 shares of OPK an 175000 of COCP

    by freetoquestionu Oct 19, 2015 12:27 PM
    debdoesbios debdoesbios Oct 19, 2015 1:24 PM Flag

    We come a long ways, since ASTX. That win gave us so much bargaining power. We made like 8x our money there while rory took a bath. Not that he didn't need one.

  • Reply to

    Have 40,000 shares of OPK an 175000 of COCP

    by freetoquestionu Oct 19, 2015 12:27 PM
    debdoesbios debdoesbios Oct 19, 2015 12:34 PM Flag

    It was smart of us to sell in the $18's and buy OPK in the$8's. Billy called it perfect. Letting go of COCP above $1.40 was also another of his great calls. Buying it back in the .70 is like frosting on the cake. Plus we all got in on the ground floor of Svac.

  • Reply to

    Clowns I'm over here now

    by svacfakeid39s57 Oct 19, 2015 10:29 AM
    debdoesbios debdoesbios Oct 19, 2015 10:45 AM Flag

    Told you this would frustrate him.

  • debdoesbios by debdoesbios Jul 10, 2015 1:56 PM Flag

    Always liked it when the field was him with 5 id's and everyone else with one. That is how he operates. He has lied so many times and when anyone confront's him, he uses another id. So what billy has skillfully done, is take away his escapes, till like always he uses the last one remaining. Ignore.

  • Reply to

    They had the funeral yesterday

    by billyteex1 Jul 10, 2015 8:39 AM
    debdoesbios debdoesbios Jul 10, 2015 9:42 AM Flag

    Shameless. Interesting how you know that rory will always take the opposite position to anything you write. Just like clock work, he had to think Trump is wrong about the borders. Do you get a sense sometimes this is just too easy. On ASTX he was always pulling his hair out with you pulling his strings.

  • Reply to

    Old Gold Bug

    by billyteex1 Jul 10, 2015 8:36 AM
    debdoesbios debdoesbios Jul 10, 2015 9:37 AM Flag

    So this is Rory? How did you screw up that ASTX investment like you did. You were the only investor in 8 years to walk away broke from it. Looks like nothing has changed in your life. You always are running and hiding behind numerous id's. Best part here, if you let anything slip we own you. The little birdie still talking to you?

    Glad to see billy and arql are playing with you. Do you still use the escrow ploy when you get in trouble. That was always one of your games. Glad to see that you have not grown up. The first time we met you on supergen, you were claiming to own 80K shares of supergen at $8 range. However when you showed the one time any trades, you were on margin with trades as little as 200 shares.

    All that big talk about 80K shares and you barely could afford a $2 stock. We will relive your past. I hold such vivid memories.

    Billy nice call on Levon. Did you just stumble on rory here?

  • Reply to

    This is that filter company

    by debdoesbios Jul 9, 2015 5:23 PM
    debdoesbios debdoesbios Jul 9, 2015 5:30 PM Flag

    I erased your posted replies. You can waste energy replying, but I will not allow them to remain. We have a way with dealing with Roryrae and it's on our terms only. Please keep us on ignore and we'll all get along. How could this guy be this stupid twice. Unreal.

  • Is this the one where you made a quick 100% years ago? You still following it, why? The financials look horrible. No wonder they need multiple id's to pump. So who would hang on to this, from 2009? It also looks like they have done numerous RO's. CEO was fired.

    Funny, all the id's that say they have you on ignore are replying. They can't your post will not show up. If you made $125K years ago here, then you did real well. How come billy you bought back in or did you. You just messing with him? I would like to see that list and details about each ID. Can you have it for me in the morning?

  • debdoesbios by debdoesbios Apr 29, 2013 4:00 PM Flag

    Longs it's been a long road. I want to thank Free for keeping us up to date all these years. He had to battle the likes of rory and batzem and in the end, looks like Free was right. He knew at $2 this was a bargain and he lend the charge all these years. Without his positive comments on the pipeline, most of you would have packed it up.

    Again thank you Free. You the best.

    Sentiment: Strong Buy

  • Reply to

    Posted this a few weeks ago

    by debdoesbios Feb 26, 2013 11:15 AM
    debdoesbios debdoesbios Feb 26, 2013 4:53 PM Flag

    Max,

    I spent the past half hour looking on the FDA's website. They have a generic approval and tentative approval on their site. I was looking through for anything on dacogen and vidaza. I don't see any approvals for a generic drug. If you have time google FDA heneric approvals. It was the first site in the list. They have to update it, the last time was Jan3. You can go deeper into the site and look at tentative approvals for generics. They have to get approval from the FDA at some point.

    Sentiment: Buy

  • Reply to

    Posted this a few weeks ago

    by debdoesbios Feb 26, 2013 11:15 AM
    debdoesbios debdoesbios Feb 26, 2013 11:29 AM Flag

    I'm surprised the street is taking the dacogen generic news so well. Specially with it flirting with $3. They mention Buckmans name in the Q&A yesterday, but no one asked him a single question. The main questions was about SGI-110 and the three areas it could seek approval. The analyst ask a question about Registration stategy, maybe someone knows what that's about.

    Here are the 3 options on SGI-110

    Untreated int/high MDS
    Elderly AML
    Relaspe AML(5 responders were from this group)

    Dacogen both got approved on Responce rate. Later Vidaza on Survival.

    The key yesterday is they will announce by EOY the pathway. I think $57M in Dacogen sales in the EU is a great start. They have 18,000 AML pts and 10,000 that qualify for dacogen.

    Sentiment: Buy

  • debdoesbios by debdoesbios Feb 26, 2013 11:15 AM Flag

    Published: Friday, Jan 4, 2013, 3:55 IST
    By KV Ramana | Place: Hyderabad | Agency: DNA

    Pharma major Dr Reddy’s Laboratories has embarked on yet another 180-day exclusivity opportunity with the launch of its Finasteride tablets in the US market.

    Finasteride, which is marketed by a Merck subsidiary under Propecia brand, had an estimated $136 million sales for 12 months ended October 2012. Dr Reddy’s would market the 1 mg tablets in the bottle counts of 30 and 90.

    Under the exclusivity, Dr Reddy’s would be the only company other than the innovator to market the drug for six months in the US.

    However, analysts are wary of the price erosion on introduction of the generic drug.

    Finasteride is indicated for the treatment of benign prostatic hyperplasia and male pattern baldness.

    Meantime, the company is expected to receive approvals for yet another limited competition drug – azacitidine (brandname Vidaza) — in the US market this quarter.

    “Azacitidine brand size is $340 million and both patent and marketing exclusivity have expired. Dr Reddy’s filed DMF (drug master file) in February 2010 and could get approval any time,” wrote Anubhav Aggarwal and Chunky Shah, analysts with Credit Suisse on Thursday.

    At 50% price erosion and a 50% market share, Azacitidine could be a $65 million opportunity for Dr Reddy’s and competition is likely to remain limited before Teva enters after two years, they said.

    Analysts also expect another drug Metoprolol to start contributing significantly to the revenue. “Higher Metoprolol sales should start in the middle of this quarter. We expect $60 million annualised contribution with margins of about 90%,” the Credit Suisse analyst said.

    Sentiment: Buy

  • Reply to

    SEC filing

    by debdoesbios Feb 10, 2013 2:18 PM
    debdoesbios debdoesbios Feb 10, 2013 3:02 PM Flag

    Found this. it may explain why walter lack would exercize options at a higher amount than if he bought shares in the open market:

    If the employee wishes to profit from the stock option awards, the eligible options must be purchased at the agreed-upon strike price. For example, if an employee has 1,000 options with a $1 exercise price, the employee must pay $1,000 to the company to receive the underlying shares of common stock. The acquiring company may impose a deadline by which options must be exercised prior to closing. Failure to exercise the options may result in employee forfeiture of the option awards. There are many ways this transaction can happen. The employee can write a check to the company out of his bank account, the amount may be withheld from an employee's paycheck, the company may provide a bridge loan to the employee to be repaid when the employee sells the shares of stock during the acquisition, or opt to receive an adjusted number of shares of stock to compensate for the exercise price.

    We can dream. I would not get over excited.

    Sentiment: Buy

  • debdoesbios by debdoesbios Feb 10, 2013 2:18 PM Flag

    It looks like Walter Lack bought some more shares. In June last year he exercized 35,000 shares. Well on Friday he was at it again, exercizing 42,500 shares. He now owns 457,500.

    Looking at the filing, he decided to exercize 7500 shares at $3.97. The rest 35,000 shares at $2.92.

    Why would he spend $3.97 for shares, he could just buy in the market at $3.39?

    Sentiment: Buy

  • Reply to

    Last Message to KY HATE FREE DEB

    by batzem Feb 8, 2013 2:31 PM
    debdoesbios debdoesbios Feb 10, 2013 1:47 PM Flag

    You have to be impressed with the class that batzem displays. In his parting shot, he wishes bad luck on all investors of ASTX. Instead of just stating he decided to limit his exposer to a generic copy, this week batzem stated we would see a 70% drop in revenues for dacogen starting in May. He now predicts a 30-50% drop in the share price. The funny part for the past few months, it's all been negativity from batzem. The shares he claimed he owned were increasing in value, but the negativity continued. Strange behavior.

    I did some research this afternoon on generics. I found that article about vidaza going generic. But nothing on dacogen. Eisai has a division that is generic drugs. I wonder if they will just generic drive this, themselves? What that would mean too ASTX, I don't have that answer. But just the threat of the eisai being able to keep this drug sales going, under a generic label, well that maybe something other generic companies do not want to find out. I as an investor want to look at all angles.

    My last point, this maybe the right time for Dr. M to shop this. A larger company would not be impacted by a generic, as much as ASTX, right now. The aml approval will cover some of the generic exposer, but not all of it. This should been title second last message to us.

    We all wish batzem the best.

    Sentiment: Buy

  • Reply to

    Batzem states GENERIC on The Way

    by kyjellie Feb 7, 2013 7:57 PM
    debdoesbios debdoesbios Feb 7, 2013 10:10 PM Flag

    free,

    Here is the newest on Vidaza and Dr. Reddy's. On the master drug list...Dr. Reddys not listed for azacitidine. I felt that this is a topic that needed to be explored, since it could affect my shares. Maybe if Batzem used his mind instead of idiotic remarks, we all could learn something. I have not found anything that anyone has launch a dacogen generic. It would seem that Eisai would have to disclose any generic threat. If we use the same math on dacogen that they did here on vidaza, the opportunity for Dr. Reddys on dacogen would be around the $55M . It seems that Batzem is a little thin skinned. Well it's not a perfect world. I bite my lip on numerous occassions. But it looks like batzem could be right. Before batzems heads swells up, I found this in a few seconds, you had 24 hours. I would explain to you my method, but feel you would not understand. BTW batzem, I post over 5 years ago, where to find generic news on decitabine. So most likely you learned it from me.

    Dr Reddy’s starts mining $136 million drug exclusivity

    Published: Friday, Jan 4, 2013, 3:55 IST
    By KV Ramana | Place: Hyderabad | Agency: DNA

    Pharma major Dr Reddy’s Laboratories has embarked on yet another 180-day exclusivity opportunity with the launch of its Finasteride tablets in the US market.

    Finasteride, which is marketed by a Merck subsidiary under Propecia brand, had an estimated $136 million sales for 12 months ended October 2012. Dr Reddy’s would market the 1 mg tablets in the bottle counts of 30 and 90.

    Under the exclusivity, Dr Reddy’s would be the only company other than the innovator to market the drug for six months in the US.

    However, analysts are wary of the price erosion on introduction of the generic drug.

    Finasteride is indicated for the treatment of benign prostatic hyperplasia and male pattern baldness.

    Meantime, the company is expected to receive approvals for yet another limited competition drug – azacitidine (brandname Vidaza) — in the US market this quarter.

    “Azacitidine brand size is $340 million and both patent and marketing exclusivity have expired. Dr Reddy’s filed DMF (drug master file) in February 2010 and could get approval any time,” wrote Anubhav Aggarwal and Chunky Shah, analysts with Credit Suisse on Thursday.

    At 50% price erosion and a 50% market share, Azacitidine could be a $65 million opportunity for Dr Reddy’s and competition is likely to remain limited before Teva enters after two years, they said.

    Analysts also expect another drug Metoprolol to start contributing significantly to the revenue. “Higher Metoprolol sales should start in the middle of this quarter. We expect $60 million annualised contribution with margins of about 90%,” the Credit Suisse analyst said.

    Sentiment: Buy

  • Reply to

    Wow

    by kyjellie Jan 19, 2013 7:50 AM
    debdoesbios debdoesbios Jan 21, 2013 10:21 AM Flag

    Excellent post. The street would welcome some insiders getting on board. If Jhoti, Dr. M and a few others starting using these options, that is a strong sign.

    Sentiment: Strong Buy

  • Reply to

    Covered calls

    by kyjellie Jan 21, 2013 9:39 AM
    debdoesbios debdoesbios Jan 21, 2013 10:17 AM Flag

    free,

    I believe he already lost those shares on Thursday. He probably wrote the $2.50's and needs the share price to fall, so he can get them back. Why else would he claim he's long, but bash it at the same time? If there's one guy stupid enough to try and make a few bucks on covered calls, it's rory. It backfired on him. This is why the attacks on ky. If rory was long, why would he attack you personally? The best medicine is insiders to start buying heavily.

    A partnership deal maybe in the works, this would move astx above $4, maybe even $5. Throw in some institutions wanting to get on board, this dilution on Friday, was a premptive move. They didn't do it because they needed funds, that's for sure.

    Sentiment: Strong Buy

  • Reply to

    Tweedle dee visit tweedle dum

    by lovinfriendship Dec 21, 2012 2:19 PM
    debdoesbios debdoesbios Dec 21, 2012 2:32 PM Flag

    Think others should also report him to yahoo. Thanks